<DOC>
	<DOCNO>NCT02271204</DOCNO>
	<brief_summary>This observational study ass safety intravenous Ibandronate ( Bonviva ) intermittent administration patient postmenopausal osteoporosis efficacy IV Ibandronate ( Bonviva treatment relative lumbar spine hip bone mineral densitometry form baseline year 1 )</brief_summary>
	<brief_title>Observational Study iv Ibandronate Women With Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>Patients post menopausal osteoporosis Patients contraindication bisphosphonates Patients naive ibandronate therapy Patients sign informed consent willing share data data analysis Is Ibandronate na√Øve Hypersensitivity component bisphosphonates Ibandronate ; Administration investigational drug within 30 day precede first dose study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>